Titrated Oxygen
Phase 3Small molecule
Titrated Oxygen is one of 39 small molecule programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
120 competitors in Chronic Obstructive Pulmonary Disease
#DrugCompanyPhaseTrials
1EXDENSUR
GGlaxo Dba Glaxosmithkline
Phase 3
Lunsekimig
SanofiPhase 3
Tozorakimab
AstraZenecaPhase 3
CM310
KKeymed Biosciences Co.Ltd
Phase 3
Sildenafil ODT
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Astegolimab
RochePhase 3
Titrated Oxygen
RRigshospitalet, Denmark
Phase 3
Calciferol
Jazz PharmaceuticalsPreclinical
Duragesic
CCephalon
Preclinical
TQC2731
SShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Titrated Oxygen. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- RRigshospitalet, Denmark